Continuing semaglutide after initiating dialysis is safe and associated with lower rates of serious adverse events and ...

Researchers say knowing that semaglutide improves liver health independently of weight loss could influence prescribing decisions.

Compared with placebo, semaglutide lowered risks for adverse kidney outcomes and mortality across the chronic kidney disease spectrum, according to study data published in Clinical Journal of the ...

Semaglutide improves liver health by targeting specific receptors, reducing inflammation and scarring independently of its ...

Researchers at Toronto's Sinai Health have found that semaglutide – the active ingredient in popular weight loss drugs that ...

Researchers from Toronto’s Sinai Health have published a study that sheds light on a central mystery for scientists studying ...

AIIMS Professor emphasizes that lifestyle changes are essential, as Semaglutide cannot replace healthy habits for effective ...

Trials of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, are documenting its direct kidney effects and broad benefits for diabetic kidney disease.

Semaglutide, the active ingredient in GLP-1 weight loss drugs, directly improves liver function through a specific subset of ...

Researchers have found that semaglutide, the active ingredient in popular weight loss drugs that mimic the gut hormone GLP-1, ...

Clinical trials suggest that about 10% to 15% of people who try GLP-1s don't lose weight. But evidence is building that shows ...